Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study

BACKGROUND: Oclacitinib is an orally bioavailable Janus Kinase (JAK) inhibitor approved for the treatment of canine atopic dermatitis. Aberrant JAK/ Signal Transducer and Activator of Transcription (STAT) signaling within hematologic and solid tumors has been implicated as a driver of tumor growth t...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrett, Laura E., Gardner, Heather L., Barber, Lisa G., Sadowski, Abbey, London, Cheryl A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693187/
https://www.ncbi.nlm.nih.gov/pubmed/31409327
http://dx.doi.org/10.1186/s12917-019-2032-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693187/
https://www.ncbi.nlm.nih.gov/pubmed/31409327
http://dx.doi.org/10.1186/s12917-019-2032-4

Ejemplares similares